1437 related articles for article (PubMed ID: 30736840)
21. FBI-1 enhanced the resistance of triple-negative breast cancer cells to chemotherapeutic agents via the miR-30c/PXR axis.
Yang H; Ren L; Wang Y; Bi X; Li X; Wen M; Zhang Q; Yang Y; Jia Y; Li Y; Zang A; Wei Y; Dai G
Cell Death Dis; 2020 Oct; 11(10):851. PubMed ID: 33051436
[TBL] [Abstract][Full Text] [Related]
22. MicroRNA-211-5p suppresses tumour cell proliferation, invasion, migration and metastasis in triple-negative breast cancer by directly targeting SETBP1.
Chen LL; Zhang ZJ; Yi ZB; Li JJ
Br J Cancer; 2017 Jun; 117(1):78-88. PubMed ID: 28571042
[TBL] [Abstract][Full Text] [Related]
23. The Role and Mechanism of CRT0066101 as an Effective Drug for Treatment of Triple-Negative Breast Cancer.
Liu Y; Wang Y; Yu S; Zhou Y; Ma X; Su Q; An L; Wang F; Shi A; Zhang J; Chen L
Cell Physiol Biochem; 2019; 52(3):382-396. PubMed ID: 30845378
[TBL] [Abstract][Full Text] [Related]
24. Tumor suppressor role of microRNA-1296 in triple-negative breast cancer.
Phan B; Majid S; Ursu S; de Semir D; Nosrati M; Bezrookove V; Kashani-Sabet M; Dar AA
Oncotarget; 2016 Apr; 7(15):19519-30. PubMed ID: 26799586
[TBL] [Abstract][Full Text] [Related]
25. Doubling down on the PI3K-AKT-mTOR pathway enhances the antitumor efficacy of PARP inhibitor in triple negative breast cancer model beyond BRCA-ness.
De P; Sun Y; Carlson JH; Friedman LS; Leyland-Jones BR; Dey N
Neoplasia; 2014 Jan; 16(1):43-72. PubMed ID: 24563619
[TBL] [Abstract][Full Text] [Related]
26. Targeting SET to restore PP2A activity disrupts an oncogenic CIP2A-feedforward loop and impairs triple negative breast cancer progression.
Liu CY; Huang TT; Chen YT; Chen JL; Chu PY; Huang CT; Wang WL; Lau KY; Dai MS; Shiau CW; Tseng LM
EBioMedicine; 2019 Feb; 40():263-275. PubMed ID: 30651219
[TBL] [Abstract][Full Text] [Related]
27. Synthetic Lethality Exploitation by an Anti-Trop-2-SN-38 Antibody-Drug Conjugate, IMMU-132, Plus PARP Inhibitors in
Cardillo TM; Sharkey RM; Rossi DL; Arrojo R; Mostafa AA; Goldenberg DM
Clin Cancer Res; 2017 Jul; 23(13):3405-3415. PubMed ID: 28069724
[No Abstract] [Full Text] [Related]
28. High Myc expression and transcription activity underlies intra-tumoral heterogeneity in triple-negative breast cancer.
Gupta N; Jung K; Wu C; Alshareef A; Alqahtani H; Damaraju S; Mackey JR; Ghosh S; Sabri S; Abdulkarim BS; Bigras G; Lai R
Oncotarget; 2017 Apr; 8(17):28101-28115. PubMed ID: 28427212
[TBL] [Abstract][Full Text] [Related]
29. CircRNA_069718 promotes cell proliferation and invasion in triple-negative breast cancer by activating Wnt/β-catenin pathway.
Zhang J; Xu HD; Xing XJ; Liang ZT; Xia ZH; Zhao Y
Eur Rev Med Pharmacol Sci; 2019 Jun; 23(12):5315-5322. PubMed ID: 31298383
[TBL] [Abstract][Full Text] [Related]
30. LINC01638 lncRNA activates MTDH-Twist1 signaling by preventing SPOP-mediated c-Myc degradation in triple-negative breast cancer.
Luo L; Tang H; Ling L; Li N; Jia X; Zhang Z; Wang X; Shi L; Yin J; Qiu N; Liu H; Song Y; Luo K; Li H; He Z; Zheng G; Xie X
Oncogene; 2018 Nov; 37(47):6166-6179. PubMed ID: 30002443
[TBL] [Abstract][Full Text] [Related]
31. MYC suppresses STING-dependent innate immunity by transcriptionally upregulating DNMT1 in triple-negative breast cancer.
Wu SY; Xiao Y; Wei JL; Xu XE; Jin X; Hu X; Li DQ; Jiang YZ; Shao ZM
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34321275
[TBL] [Abstract][Full Text] [Related]
32. MAPK4 silencing together with a PARP1 inhibitor as a combination therapy in triple‑negative breast cancer cells.
Zeng X; Jiang S; Ruan S; Guo Z; Guo J; Liu M; Ye C; Dong J
Mol Med Rep; 2021 Aug; 24(2):. PubMed ID: 34080025
[TBL] [Abstract][Full Text] [Related]
33. BRD4 modulates vulnerability of triple-negative breast cancer to targeting of integrin-dependent signaling pathways.
Zhang Y; Xu B; Shi J; Li J; Lu X; Xu L; Yang H; Hamad N; Wang C; Napier D; He S; Liu C; Liu Z; Qian H; Chen L; Wei X; Zheng X; Huang JA; Thibault O; Craven R; Wei D; Pan Y; Zhou BP; Wu Y; Yang XH
Cell Oncol (Dordr); 2020 Dec; 43(6):1049-1066. PubMed ID: 33006750
[TBL] [Abstract][Full Text] [Related]
34. The circRNA circSEPT9 mediated by E2F1 and EIF4A3 facilitates the carcinogenesis and development of triple-negative breast cancer.
Zheng X; Huang M; Xing L; Yang R; Wang X; Jiang R; Zhang L; Chen J
Mol Cancer; 2020 Apr; 19(1):73. PubMed ID: 32264877
[TBL] [Abstract][Full Text] [Related]
35. MicroRNA-101 inhibits cell progression and increases paclitaxel sensitivity by suppressing MCL-1 expression in human triple-negative breast cancer.
Liu X; Tang H; Chen J; Song C; Yang L; Liu P; Wang N; Xie X; Lin X; Xie X
Oncotarget; 2015 Aug; 6(24):20070-83. PubMed ID: 26036638
[TBL] [Abstract][Full Text] [Related]
36. Cip2a promotes cell cycle progression in triple-negative breast cancer cells by regulating the expression and nuclear export of p27Kip1.
Liu H; Qiu H; Song Y; Liu Y; Wang H; Lu M; Deng M; Gu Y; Yin J; Luo K; Zhang Z; Jia X; Zheng G; He Z
Oncogene; 2017 Apr; 36(14):1952-1964. PubMed ID: 27694903
[TBL] [Abstract][Full Text] [Related]
37. Kynurenine 3-monooxygenase upregulates pluripotent genes through β-catenin and promotes triple-negative breast cancer progression.
Huang TT; Tseng LM; Chen JL; Chu PY; Lee CH; Huang CT; Wang WL; Lau KY; Tseng MF; Chang YY; Chiang TY; Ueng YF; Lee HC; Dai MS; Liu CY
EBioMedicine; 2020 Apr; 54():102717. PubMed ID: 32268268
[TBL] [Abstract][Full Text] [Related]
38. MYC and DNMT3A-mediated DNA methylation represses microRNA-200b in triple negative breast cancer.
Pang Y; Liu J; Li X; Xiao G; Wang H; Yang G; Li Y; Tang SC; Qin S; Du N; Zhang H; Liu D; Sun X; Ren H
J Cell Mol Med; 2018 Dec; 22(12):6262-6274. PubMed ID: 30324719
[TBL] [Abstract][Full Text] [Related]
39. CircPLK1 sponges miR-296-5p to facilitate triple-negative breast cancer progression.
Kong Y; Yang L; Wei W; Lyu N; Zou Y; Gao G; Ou X; Xie X; Tang H
Epigenomics; 2019 Aug; 11(10):1163-1176. PubMed ID: 31337246
[No Abstract] [Full Text] [Related]
40. RB loss contributes to aggressive tumor phenotypes in MYC-driven triple negative breast cancer.
Knudsen ES; McClendon AK; Franco J; Ertel A; Fortina P; Witkiewicz AK
Cell Cycle; 2015; 14(1):109-22. PubMed ID: 25602521
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]